Correlation of 18F-fluoromisonidazole PET findings with HIF-1α and p53 expressions in head and neck cancer: Comparison with 18F-FDG PET

Nuclear Medicine Communications

Volumn 35, Issue 1, 2014, Pages 30-35

  Norikane, Takashi ^a   Yamamoto, Yuka ^a   Maeda, Yukito ^a   Kudomi, Nobuyuki ^b   Matsunaga, Toru ^b   Haba, Reiji ^b   Iwasaki, Akinori ^b   Hoshikawa, Hiroshi ^a   Nishiyama, Yoshihiro ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b Department of Medical Physics ^*  (Japan)

Author keywords

2 deoxy 2 18F fluoro D glucose; 18F fluoromisonidazole; Head and neck cancer; Hypoxia inducible factor 1 ; P53

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; FLUORODEOXYGLUCOSE F 18; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN P53;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; MALE; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL TRANSPORT; FEMALE; FLUORODEOXYGLUCOSE F18; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MIDDLE AGED; MISONIDAZOLE; POSITRON-EMISSION TOMOGRAPHY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84889257100     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0000000000000010     Document Type: Article

References (32)

1. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet 2008; 371:1695-1709. (Pubitemid 351671886)
2. Molinolo AA, Amornphimoltham P, Squarize CH, Castilho RM, Patel V, Gutkind JS. Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol 2009; 45:324-334.
3. Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology 2004; 231:305-332. (Pubitemid 38552885)
4. Hain SF. Positron emission tomography in cancer of the head and neck. Br J Oral Maxillofac Surg 2005; 43:1-6. (Pubitemid 40090164)
5. Wenger RH, Camenisch G, Desbaillets I, Chilov D, Gassmann M. Up-regulation of hypoxia-inducible factor-1α is not sufficient for hypoxic/anoxic p53 induction. Cancer Res 1998; 58:5678-5680. (Pubitemid 29006404)
6. Ruan K, Song G, Ouyang G. Role of hypoxia in the hallmarks of human cancer. J Cell Biochem 2009; 107:1053-1062.
7. Brown MJ. The hypoxic cell: a target for selective cancer therapy. Eighteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 1999; 59:5863-5870.
8. Stadler P, Becker A, Feldmann HJ, Hänsgen G, Dunst J, Würschmidt F, et al. Influence of the hypoxic subvolume on the survival of patients with head and neck cancer. Int J Radiat Oncol Biol Phys 1999; 44:749-754. (Pubitemid 29284123)
9. 18F-fluoromisonidazole. Int J Radiat Oncol Biol Phys 1992; 22:199-212.
10. 18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 1996; 36:417-428.
11. 18F-Fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma. Ann Nucl Med 2011; 25: 625-633.
12. 2-polarography in metastatic head and neck cancer. Eur J Nucl Med Mol Imaging 2006; 33:1426-1431. (Pubitemid 44885408)
13. Rajendran JG, Schwartz DL, O'Sullivan J, Peterson LM, Ng P, Scharnhorst J, et al. Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res 2006; 12:5435-5441. (Pubitemid 44497258)
14. 18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. Radiother Oncol 2006; 80:151-156. (Pubitemid 44301544)
15. Hicks RJ, Rischin D, Fisher R, Binns D, Scott AM, Peters LJ. Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent. Eur J Nucl Med Mol Imaging 2005; 32:1384-1391. (Pubitemid 41746841)
16. Rischin D, Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S, et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 2006; 24:2098-2104. (Pubitemid 46622121)
17. 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer. BMC Cancer 2005; 5: 152-160.
18. Yeh SH, Liu RS, Wu LC, Yang DJ, Yen SH, Chang CW, et al. Fluorine-18 fluoromisonidazole tumour to muscle retention ratio for the detection of hypoxia in nasopharyngeal carcinoma. Eur J Nucl Med 1996; 23: 1378-1383. (Pubitemid 26340592)
19. 18F]FMISO-PET in HNSCC. When is the contrast best? Nuklearmedizin 2011; 50:22-27.
20. 18F-Fluoromisonidazole PET uptake is correlated with hypoxia-inducible factor-1α expression in oral squamous cell carcinoma. J Nucl Med 2013; 54:1060-1065.
21. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, et al. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res 1999; 59:5830-5835.
22. Baas IO, Hruban RH, Offerhaus GJA. Clinical applications of detecting dysfunctional p53 tumor suppressor protein. Histol Histopathol 1999; 14:279-284. (Pubitemid 29049375)
23. 18F]FDG module. Nucl Med Biol 2005; 32:899-905. (Pubitemid 41505324)
24. 18F]fluoro-D-glucose by direct nucleophilic exchange on a quaternary 4-aminopyridinium resin. Nucl Med Biol 1990; 17:273-279. (Pubitemid 20110114)
25. 18F-FDG PET. J Nucl Med 2006; 47:1921-1926. (Pubitemid 47544979)
26. Sumiyoshi Y, Kakeji Y, Egashira A, Mizokami K, Orita H, Maehara Y. Overexpression of hypoxia-inducible factor 1α and p53 is a marker for an unfavorable prognosis in gastric cancer. Clin Cancer Res 2006; 12: 5112-5117. (Pubitemid 44453338)
27. Schmid T, Zhou J, Brune B. HIF-1 and p53: communication of transcription factors under hypoxia. J Cell Mol Med 2004; 8:423-431. (Pubitemid 44145475)
28. Brennan JA, Mao L, Hruban RH, Boyle JO, Eby YJ, Koch WM, et al. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med 1995; 332:429-435.
29. 18F-FDG PET, and immunohistochemical studies. J Nucl Med 2006; 47:410-418. (Pubitemid 46768482)
30. 4- methylthiosemicarbazone) PET imaging to predict highly malignant tumor grades and hypoxia-inducible factor-1α expression in patients with glioma. AJNR Am J Neuroradiol 2013; 34: 92-99.
31. Crippa F, Seregni E, Agresti R, Chiesa C, Pascali C, Bogni A, et al. Association between [F-18]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med 1998; 25:1429-1434. (Pubitemid 28464119)
32. Buck A, Schirrmeister H, Kühn T, Shen C, Kalker T, Kotzerke J, et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging 2002; 10:1317-1323. (Pubitemid 44392212)